BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Pfizer Inc. (PFE) Seeks to Cut $1 Billion in Costs; Cuts are in Addition to Those Previously Announced in the Company's R&D Ops


6/8/2011 8:01:14 AM

Pfizer, which has operations in St. Louis, is looking to cut $1 billion in costs, CEO Ian Read told The Wall Street Journal.

About $500 million in annual expenses will be cut this year and another $500 million will be cut next year, sources told the Journal.

"The newest cost-cutting initiative aims to reduce administrative work that is duplicated at Pfizer's headquarters in New York City and in offices around the world," the Journal reports. "Also under review, the people said, are spending for promotion, travel, entertainment and consultants, and sales representatives' spending on printed materials, supplies and electronic gear."

Pfizer's selling, informational and administrative expenses totaled nearly $20 billion last year.

This is the latest in cost cuts the pharmaceutical giant is making in response to its drugs losing their exclusivity. Its $3.8 billion antidepressent, Effexor, went off patent last year, and later this year, blockbuster cholesterol drug Lipitor, which had $10.7 billion in sales last year, will face generic competition.

Pfizer cut about 600 jobs from its once 1,000-member work force in Chesterfield, Mo., as part of the pharmaceutical firm’s larger plan to eliminate more than 19,000 jobs and reduce costs by $5 billion by the end of 2012, following its $68 billion Wyeth acquisition.




   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES